Clear Cell Renal Cell Carcinoma 2024–2025

Dear Colleagues,

Clear cell renal cell carcinoma is one of the most interesting areas of study in oncology right now. Despite recent advances, these tumors continue to present a health problem of major concern in Western societies, seriously affecting public health services. The characteristics of this tumor make it an exciting field for translational collaboration between clinicians and basic researchers.

Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. It is also a model of hypoxia-related carcinogenesis. The latest findings on the spatial and temporal evolutionary patterns detected in this tumor are opening up possibilities for more successful treatments. In addition, the identification of metastatic phenotypes will allow for the early detection of aggressive genotypes, guiding specific patient management.

This tumor presents an excellent model for investigating the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. Analyzing internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizes, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Finally, alternative approaches such as game theory have provided, in recent years, promising mathematical models that can be used to unveil the diversity of possible behaviors of this polyedrical disease.

Clear cell renal cell carcinoma also encompasses a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway in this area.

This Special Issue intends to serve as a multidisciplinary platform where urologists, oncologists, pathologists, radiologists, and basic researchers interested in clear cell renal cell carcinoma may meet and collaborate.

Dr. José I. López
Dr. Claudia Manini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• clear cell renal cell carcinoma
• pathology
• diagnosis
• hypoxia
• intratumor heterogeneity
• immune checkpoint blockage antiangiogenic therapy